Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Solid BiosciencesSLDB +1.31%34 Cash-to-Debt is 18.74 as of Jun. 2026, which is 59% above its 10-year median of 11.82. GuruFocus rates SLDB with a GF Score™ of 34/100. The stock has 3 warning signs investors should review. Among 1,398 Biotechnology companies, Solid Biosciences ranks better than 61.44% on this metric.
Cash to Debt Ratio measures the financial strength of a company. It is calculated as a company's cash, cash equivalents, and marketable securities divide by its debt. Solid Biosciences's cash to debt ratio for the quarter that ended in Jun. 2026 was 18.74.
If Cash to Debt ratio is greater than 1, the company can pay off its debt using the cash in hand. Here we can see, Solid Biosciencescould pay off its debt using the cash in hand for the quarter that ended in Jun. 2026.
The historical rank and industry rank for Solid Biosciences's Cash-to-Debt or its related term are showing as below:
SLDB'
s Cash-to-Debt Range Over the Past 10 Years
Min: 4.39 Med: 11.82 Max: No Debt
Current: 18.74
During the past 11 years, Solid Biosciences's highest Cash to Debt Ratio was No Debt. The lowest was 4.39. And the median was 11.82.
SLDB's Cash-to-Debt is ranked better than 61.44% of 1398
companies
in the Biotechnology industry
Industry Median: 6.575
vs SLDB: 18.74
If Cash to Debt ratio is greater than 1, the company can pay off its debt using the cash in hand. If it is smaller than 1, it means the company has more debt than the cash in hands. In this case, it is important to look the the company's Interest Coverage. Ben Graham requires that a company must have an Interest Coverage of at least 5.
Solid Biosciences Cash-to-Debt Related Terms
Solid Biosciences Cash-to-Debt Historical Data
* Premium members only.
The historical data trend for Solid Biosciences's Cash-to-Debt can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Note: An indication of "No Debt" does not necessarily mean that the company has no debt obligations; it could be due to missing data in the quarterly or annual report. Use caution when interpreting this information.
For the Biotechnology subindustry, Solid Biosciences's Cash-to-Debt, along with its competitors' market caps and Cash-to-Debt data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Solid Biosciences Cash-to-Debt vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Solid Biosciences's Cash-to-Debt distribution charts can be found below:
* The bar in red indicates where Solid Biosciences's Cash-to-Debt falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Solid Biosciences (SLDB) has a Cash-to-Debt of 18.74 as of Jun. 2026. This is 59% above median its historical median of 11.82. Over the past decade, Solid Biosciences' Cash-to-Debt has ranged from 4.39 to 10,000.00. According to the industry distribution chart, Solid Biosciences ranks #539 out of 1398 companies in the Biotechnology industry, placing it in the top 38.6%.
Is Solid Biosciences' Cash-to-Debt too high?
Solid Biosciences' current Cash-to-Debt of 18.74 is 59% above median its 10-year median of 11.82. Over the past 10 years, this metric has ranged from a low of 4.39 to a high of 10,000.00. The Biotechnology industry median Cash-to-Debt is 6.58. Solid Biosciences' value of 18.74 is 185% above this industry median. Based on the distribution chart, Solid Biosciences ranks #539 out of 1398 companies in the Biotechnology industry, which is above the industry midpoint. Overall, Solid Biosciences has a GF Score™ of 34/100, reflecting its overall financial health beyond just this single metric.
How does Solid Biosciences' Cash-to-Debt compare to AVTX and SLNCF?
According to the Biotechnology industry distribution chart, Solid Biosciences ranks #539 out of 1398 companies for Cash-to-Debt. This puts Solid Biosciences in the upper half of its industry. The industry median Cash-to-Debt is 6.58. Solid Biosciences' value of 18.74 is 185% above this benchmark. Historically, Solid Biosciences' own Cash-to-Debt has ranged from 4.39 to 10,000.00 over the past decade. While the company's 10-year median is 11.82 vs. the industry median of 6.58, Solid Biosciences has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Cash-to-Debt for a Biotechnology company?
The median Cash-to-Debt among Biotechnology companies is 6.58, based on 1,398 companies in the industry. Companies in the top quartile (top 25%) have a Cash-to-Debt significantly above this median, while those in the bottom quartile fall well below. However, Cash-to-Debt should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Solid Biosciences's current Cash-to-Debt of 18.74 is 185% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Cash-to-Debt mean?
A high Cash-to-Debt can signal that a stock is expensive relative to its fundamentals. For the Biotechnology industry, the median Cash-to-Debt is 6.58 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Solid Biosciences's current Cash-to-Debt is 18.74, which is 59% above median its own 10-year median of 11.82. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Solid Biosciences stock overvalued right now?
Solid Biosciences (SLDB) has a current Cash-to-Debt of 18.74. The current Cash-to-Debt is 18.74, which is 59% above median its 10-year median of 11.82 and 185% above the Biotechnology industry median of 6.58. Solid Biosciences' overall GF Score™ is 34/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Cash-to-Debt calculated?
Cash-to-Debt is calculated from a company's financial statements. For Solid Biosciences (SLDB), the current Cash-to-Debt is 18.74 as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Solid Biosciences Inc is a life sciences company focused on advancing a portfolio of current and future gene therapy candidates, including SGT-003 for the treatment of Duchenne muscular dystrophy, SGT-212 for the treatment of Friedreich's ataxia, SGT-501 for the treatment of catecholaminergic polymorphic ventricular tachycardia, SGT-601 for the treatment of TNNT2-mediated dilated cardiomyopathy, and additional assets for the treatment of genetic cardiac and neuromuscular diseases. The majority of its current programs are designed to treat these diseases with gene transfer products. The company operates in a single segment, developing treatments through gene therapy and other means for patients with neuromuscular and cardiac diseases.
34GF Score
Get the complete analysis for SLDB
Cash-to-Debt is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
SLDB has been successfully added to your 
